TNGX Company Profile and Key Details

Tango Therapeutics, Inc. (NASDAQ:TNGX) closed at $26.72 USD, gaining $0.09 (0.34%) from the previous close of $26.63. The stock is currently mid-range between its 52-week high and low $5.77 and $34.39. With a market capitalization of about $3.32 billion, Tango Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 4.08 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Tango Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Malte Peters, the company employs approximately 137 people and listed since September 03, 2020. Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments.

TNGX has shown sold momentum, gaining 17.35% over the past week and 38.54% over the past quarter, though year-to-date performance is up 41.2%. Short-term trend indicators are bearishly aligned (SMA20 -7.96%, SMA50 2.45%, SMA200 46.9%). The stock’s 14-day RSI is 43.26 (neutral), while the ATR of 0.85 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -16.18% below its high and over 1006.8% above its low. Average 10-day trading volume of 1.82 million shares is below the 3-month average of 4.05 million, indicating normal recent market interest.

Tango Therapeutics, Inc. has 111.26 million shares outstanding. The public float is 37.40 million shares, elevated short interest at 27.39% of float. This equals 25.40 million shares. The short ratio is 14.56 days. Institutional investors hold 115.75% of the float. Insiders own 1.17%. Third Rock Ventures IV, L.P. holds 13.39 million shares, Boxer Capital, LLC has 8.20 million shares and Davis Aaron I. has 7.12 million shares. Over the past six months, insider transactions show net selling. They sold 182.03 thousand shares across 11 transactions.

Tango Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$14.93. This means the shares are trading below this model’s fair value.

Tango Therapeutics, Inc. generated EPS of -$0.92 over the past year. Five-year average earnings growth is 7.47%. Wall Street analysts project EPS growth of -5.91% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.32. Next year's EPS is expected at -$24.59. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 15 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $69.00 to $10.00. The high target offers 158.23% upside. The low target suggests -62.57% downside. The mean target is $31.18. This offers 16.69% upside. Tango Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 13, 2026, missed forecasts by 0.0%. The prior quarter beat by -6.45%. Over the last six quarters, Apple has recorded several small beats. These include 9.37% in February 27, 2025.

Tango Therapeutics, Inc. trades at a P/E ratio of -32.87, slightly below the S&P 500 average, with a price-to-sales ratio of 59.57 and a price-to-book ratio of 10.01 reflecting a rich premium to book value. The P/FCF stands at -23.82, also above market averages. Compared to sector medians, Tango Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Tango Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.91%, with price expected at $27.23 by August 07, 2026, within a range of $24.35 to $30.30 3-Month Outlook: Projected rise of 139.15%, reaching $63.90 by October 22, 2026, with a range of $63.55 to $64.15. 1-Year Outlook: Projected gain of 19.54%, with price at $31.94 by July 23, 2027, within a range of $29.80 to $34.44.

Tango Therapeutics, Inc. (NASDAQ:TNGX) shares are up 41.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tango Therapeutics, Inc. trading at a premium to the broader market with a P/E of -32.87. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $27.38, suggesting 2.47% upside. Our AI forecast model points to short-term strength (1.91% over two weeks), a medium-term rise (139.15% over three months), and a longer-term gain (19.54% over one year), with expected trading ranges indicating moderate volatility.